JP5709765B2 - 金属イオンキレート剤、それらの製造方法およびそれらの使用 - Google Patents

金属イオンキレート剤、それらの製造方法およびそれらの使用 Download PDF

Info

Publication number
JP5709765B2
JP5709765B2 JP2011553486A JP2011553486A JP5709765B2 JP 5709765 B2 JP5709765 B2 JP 5709765B2 JP 2011553486 A JP2011553486 A JP 2011553486A JP 2011553486 A JP2011553486 A JP 2011553486A JP 5709765 B2 JP5709765 B2 JP 5709765B2
Authority
JP
Japan
Prior art keywords
groups
compound
formula
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011553486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520271A5 (enExample
JP2012520271A (ja
Inventor
デラングル，パスカル
ガトー，クリステル
ピュジョル，アンエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat à l'Énergie Atomique et Aux Énergies Alternatives filed Critical Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Publication of JP2012520271A publication Critical patent/JP2012520271A/ja
Publication of JP2012520271A5 publication Critical patent/JP2012520271A5/ja
Application granted granted Critical
Publication of JP5709765B2 publication Critical patent/JP5709765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011553486A 2009-03-13 2010-03-11 金属イオンキレート剤、それらの製造方法およびそれらの使用 Active JP5709765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0901193 2009-03-13
FR0901193A FR2943060B1 (fr) 2009-03-13 2009-03-13 Agents chelatants d'ions metalliques, leurs procedes de preparation et leurs applications
PCT/FR2010/000202 WO2010103204A1 (fr) 2009-03-13 2010-03-11 Agents chelatants d'ions metalliques, leurs procedes de preparation et leurs applications

Publications (3)

Publication Number Publication Date
JP2012520271A JP2012520271A (ja) 2012-09-06
JP2012520271A5 JP2012520271A5 (enExample) 2013-03-28
JP5709765B2 true JP5709765B2 (ja) 2015-04-30

Family

ID=41130312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011553486A Active JP5709765B2 (ja) 2009-03-13 2010-03-11 金属イオンキレート剤、それらの製造方法およびそれらの使用

Country Status (4)

Country Link
EP (2) EP2982669B1 (enExample)
JP (1) JP5709765B2 (enExample)
FR (1) FR2943060B1 (enExample)
WO (1) WO2010103204A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
CR20160554A (es) 2014-05-01 2017-03-07 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del factor b del complemento
WO2015168589A2 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
AU2016349625B2 (en) 2015-11-06 2022-07-07 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
CN112094316B (zh) * 2017-06-29 2022-04-08 安徽省农业科学院农产品加工研究所 一种Ser和Cys分列在两端的高锌螯合活性锌鳌合肽及其应用
WO2025047827A1 (ja) * 2023-08-31 2025-03-06 国立大学法人東京農工大学 タンパク質フォールディング剤、化合物、タンパク質フォールディング方法、医薬組成物、及び遷移金属による細胞毒性の抑制剤
CN118715208A (zh) * 2023-10-20 2024-09-27 广东工业大学 治疗威尔逊氏病的特异性四齿铜螯合剂

Also Published As

Publication number Publication date
EP2406238A1 (fr) 2012-01-18
EP2982669A1 (fr) 2016-02-10
EP2982669B1 (fr) 2017-05-10
FR2943060B1 (fr) 2013-01-04
WO2010103204A1 (fr) 2010-09-16
JP2012520271A (ja) 2012-09-06
FR2943060A1 (fr) 2010-09-17

Similar Documents

Publication Publication Date Title
JP2012520271A (ja) 金属イオンキレート剤、それらの製造方法およびそれらの使用
DE69417426T2 (de) N2s2-chelatoren des hydrazino-typs
FR2590484A1 (fr) Sels complexes metalliques physiologiquement acceptables utilisables pour diagnostic par rmn
JP2022513392A (ja) 活性分子送達のための胆汁酸及びそれらの誘導体の抱合体
CA2746070A1 (en) Process for the preparation of asymmetrical bis(thiosemicarbazones)
CA3230165A1 (en) Inhibitor of prostate specific membrane antigen and pharmaceutical use thereof
CN114105983A (zh) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
JP7848417B2 (ja) 改良された特性を有するテトラジン類
US8148359B2 (en) Chelating agents of metal ions, their methods of preparation and their applications
KR102550339B1 (ko) Mri 영상화제로서 적합한 테트라아자비시클로-매크로사이클 기재의 망가니즈 킬레이트 화합물
AU771865B2 (en) Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use
JP2001518458A (ja) キレート化剤の親油性ジエステル
US9856294B2 (en) Cyclodecapeptide compounds for use as drugs
CA2658076C (fr) Agents chelatants d'ions metalliques, leurs procedes de preparation et leurs applications
Molenda et al. Mobilization of iron by chiral and achiral anionic 3-hydroxypyrid-4-ones
US20070185072A1 (en) Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
WO2017214680A1 (en) Adamantane compounds
JP2024520899A (ja) アルデヒドのｉｎ ｖｉｖｏ検出のための分子プローブ
AU2004202030B2 (en) New quaternary ammonium compounds, a process for their preparation and pharmaceutical compositions containing them
DE4311022A1 (de) Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
Mesterházy New peptidic Cu (I) chelators as potential candidates for the treatment of Wilson’s disease
KR100567001B1 (ko) 시스테인 유도체 및 이를 이용한 금속 트리카보닐 착화물,이들의 제조 방법 및 이들을 포함하는 조영제
Gateau et al. Rational Design of Copper and Iron Chelators to Treat Wilson's Disease and Hemochromatosis
KR19990081900A (ko) 조영제
WO2025163025A1 (en) Pyridophane macrocyclic ligands and fe(iii) complexes thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150303

R150 Certificate of patent or registration of utility model

Ref document number: 5709765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250